Biontech Se Stock Debt To Equity
0A3M Stock | USD 113.00 0.99 0.87% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech | Debt To Equity |
BioNTech SE Company Debt To Equity Analysis
BioNTech's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current BioNTech Debt To Equity | 0.05 % |
Most of BioNTech's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
BioNTech Other Stockholder Equity
Other Stockholder Equity |
|
According to the company disclosure, BioNTech SE has a Debt To Equity of 0.046%. This is 99.91% lower than that of the Biotechnology sector and 99.76% lower than that of the Health Care industry. The debt to equity for all United Kingdom stocks is 99.91% higher than that of the company.
Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
All Next | Launch Module |
BioNTech Fundamentals
Return On Equity | 0.24 | ||||
Return On Asset | 0.17 | ||||
Profit Margin | 0.48 % | ||||
Operating Margin | 0.64 % | ||||
Current Valuation | 9.83 B | ||||
Shares Outstanding | 239.77 M | ||||
Shares Owned By Insiders | 65.11 % | ||||
Shares Owned By Institutions | 17.59 % | ||||
Price To Book | 1.35 X | ||||
Price To Sales | 3.37 X | ||||
Revenue | 3.82 B | ||||
Gross Profit | 16.07 B | ||||
EBITDA | 5.94 B | ||||
Net Income | 930.3 M | ||||
Cash And Equivalents | 914.9 M | ||||
Cash Per Share | 3.75 X | ||||
Total Debt | 28.1 M | ||||
Debt To Equity | 0.05 % | ||||
Current Ratio | 2.67 X | ||||
Book Value Per Share | 83.02 X | ||||
Cash Flow From Operations | 5.37 B | ||||
Earnings Per Share | 18.00 X | ||||
Price To Earnings To Growth | 0.05 X | ||||
Target Price | 219.54 | ||||
Number Of Employees | 5.5 K | ||||
Beta | 0.24 | ||||
Market Capitalization | 30.91 B | ||||
Total Asset | 23.01 B | ||||
Retained Earnings | 19.76 B | ||||
Working Capital | 17.46 B | ||||
Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .